Valuation: CSL Limited

Market Cap 66.41B 59.28B 54.55B 49.51B 93.82B 6,225B 96.15B 653B 260B 3,333B 249B 244B 10,496B P/E 2027 *
22.9x
P/E 2028 * 20.6x
Enterprise Value 75.63B 67.51B 62.12B 56.38B 107B 7,089B 109B 743B 296B 3,795B 284B 278B 11,953B EV / Sales 2027 *
4.8x
EV / Sales 2028 * 4.61x
Free-Float
99.97%
Yield 2027 *
2.16%
Yield 2028 * 2.3%
1 day-0.23%
1 week+0.80%
Current month-0.21%
1 month+8.39%
3 months+48.96%
6 months+98.82%
Current year+16.02%
1 week 195.44
Extreme 195.435
203.13
1 month 182.27
Extreme 182.27
203.13
Current year 90
Extreme 90
203.13
1 year 90
Extreme 90
203.13
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 A Free

Director

523 0.0001%
8/26/26 A Free 317 0.0001% -
8/26/26 A Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%+0.80%+11.96%-20.56% 66.54B
+4.28%+0.07%+52.75%+138.78% 1,206B
+2.13%+4.27%+51.21%+91.36% 665B
+0.68%+1.54%+33.83%+112.47% 515B
+2.77%+0.98%+49.44%+68.46% 381B
+1.38%+0.27%+72.42%+45.30% 362B
+0.29%+1.48%+30.84%+58.32% 307B
+0.98%+1.49%+9.04%+34.78% 289B
+1.04%-0.05%+45.29%+76.18% 249B
+1.46%-0.59%+42.48%+125.82% 207B
Average +1.51%+0.39%+39.93%+73.09% 425B
Weighted average by Cap. +2.26%+0.65%+45.46%+94.22%

Financials

2027 *2028 *
Net sales 15.76B 14.06B 12.94B 11.75B 22.26B 1,477B 22.81B 155B 61.71B 791B 59.14B 57.88B 2,490B 16.31B 14.56B 13.4B 12.16B 23.04B 1,529B 23.62B 160B 63.88B 819B 61.23B 59.92B 2,578B
Net income 2.82B 2.52B 2.31B 2.1B 3.98B 264B 4.08B 27.68B 11.03B 141B 10.58B 10.35B 445B 3.14B 2.81B 2.58B 2.34B 4.44B 295B 4.55B 30.9B 12.31B 158B 11.8B 11.55B 497B
Net Debt 9.22B 8.23B 7.57B 6.87B 13.02B 864B 13.34B 90.56B 36.1B 463B 34.59B 33.85B 1,457B 8.82B 7.87B 7.24B 6.58B 12.46B 827B 12.77B 86.67B 34.54B 443B 33.11B 32.4B 1,394B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
10/11/26 A$200.74 -0.02% 422,063
09/11/26 A$200.77 -0.63% 893,443
06/11/26 A$202.04 -0.18% 1,316,473
05/11/26 A$202.40 +2.56% 1,068,429
04/11/26 A$197.34 -0.69% 782,449
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
138.67USD
Average target price
134.88USD
Spread / Average Target
-2.73%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited